NCT00093405View on ClinicalTrials.gov

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2004

Study Completion Date

November 30, 2005

Conditions
Kidney Cancer
Interventions
DRUG

tanespimycin

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00093405 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter